Impact of whole body Magnetic Resonance Imaging (MRI) in the management of melanoma patients, in comparison with positron emission tomography/computed tomography (TEP/CT) and CT;Apport de l'imagerie en résonance magnétique (IRM) du corps entier dans la prise en charge du mélanome: Comparaison avec la tomoscintigraphie par émission de positons couplée à la tomodensitométrie (TEP-TDM) et à la TDM seule

Annales de Dermatologie et de Venereologie

Volumn 138, Issue 5, 2011, Pages 377-383

  Dellestable, P ^a   Granel Brocard, F ^a   Rat, A C ^b   Olivier, P ^c   Regent D ^c   Schmutz, J L ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c CHU NANCY BRABOIS   (France)

Author keywords

Diffusion; Melanoma; MRI; Whole body

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; FEMALE; HUMAN; LIVER INJURY; LUNG LESION; MALE; MELANOMA; METASTASIS; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; WHOLE BODY MRI;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOTHERAPY; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 79955974482     PISSN: 01519638     EISSN: 01519638     Source Type: Journal    
DOI: 10.1016/j.annder.2011.02.023     Document Type: Article

References (21)

1. Brand CU, Ellwanger U, Stroebel W, Meier F, Schlagenhauff B, Rassner G, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997;79:2345-53.
2. Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002;9:646-53. (Pubitemid 34857981)
3. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998;82:1664-71. (Pubitemid 28208915)
4. Fuster D, Chiang S, Johnson G, Schuchter LM, Zhuang H, Alavi A. Is 18F-FDG-PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004;45:1323-7.
5. Wagner JD, Schauwecker D, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77:237-42. (Pubitemid 32744191)
6. Crippa F, Leutner M, Belli F, Gallino F, Pilotti S, Cascinelli N, et al. Which kinds of lymph node metastases can FDG-PET detect? A clinical study in melanoma. J Nucl Med 2000;41:1491-4.
7. Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ 3rd, Hutchins G, et al. Inefficacy of F-18 fluorodeoxy-D-glucose positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005;104:570-9. (Pubitemid 41022815)
8. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, et al. Whole body dual-modality PET/CT and whole body MRI for tumor staging in oncology. JAMA 2003;290:3199-206. (Pubitemid 38020681)
9. Schmidt GP, Baur-Melnyk A, Herzog P, Schmid R, Tiling R, Schmidt M, et al. High-resolution whole body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol 2005;40:743-53. (Pubitemid 41690430)
10. Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007;43:557-64. (Pubitemid 46177588)
11. Schmidt GP, Schoenberg SO, Schmid R, Stahl R, Tiling R, Becker CR, et al. Screening for bone metastases: whole body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 2007;17:939-49. (Pubitemid 46766875)
12. Lauenstein TC, Goehde SC, Herborn CU, Goyen M, Oberhoff C, Debatin JF, et al. Whole body MR imaging: evaluation of patients for metastases. Radiology 2004;233:139-48. (Pubitemid 39280968)
13. Goo HW, Choi SH, Ghim T, Moon HN, Seo JJ. Whole body MRI of paediatric malignant tumours: comparison with conventional oncological imaging methods. Pediatr Radiol 2005;35:766-73. (Pubitemid 41131176)
14. Muller-Horvat C, Radny P, Eigentler TK, Schafer J, Pfannenberg C, Horger M, et al. Prospective comparison of the impact on treatment decisions of whole body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer 2006;42:342-50. (Pubitemid 43132889)
15. Brady MS, Akhurst T, Spanknebel K, Hilton S, Gonen M, Patel A, et al. Utility of preoperative [(18)]f fluorodeoxyglucose positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 2006;13:525-32.
16. Gulec SA, Faries MB, Lee CC, Kirgan D, Glass C, Morton DL, et al. The role of fluorine-18-deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 2003;28:961-5. (Pubitemid 38281828)
17. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004;22:4357-68. (Pubitemid 41185156)
18. Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000;89:1019-25.
19. Bastiaannet E, Oyen WJ, Meijer S, Hoekstra OS, Wobbes T, Jager PL, et al. Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg 2006;93:243-9. (Pubitemid 43259613)
20. Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009;27:4774-80.
21. Harris MT, Berlangieri SU, Cebon JS, Davis ID, Scott AM. Impact of 2-deoxy-2[F-18]fluoro-D-glucose positron emission tomography on the management of patients with advanced melanoma. Mol Imaging Biol 2005;7:304-8.